- Home
- Equipment
- switzerland
- immunotherapeutic
Refine by
Immunotherapeutic Equipment Supplied In Switzerland
14 equipment items found
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use subcutaneous immunoglobulin (SCIg). ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use subcutaneous immunoglobulin ...
Manufactured by:Anaveon AG based inBasel, SWITZERLAND
The culmination of our research is ANV419, which is in clinical development. It is a rationally engineered fusion protein that is a stable, antibody-like molecule. ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
Liquid, ready-to-use intravenous immunoglobulin (IVIg). Indication: To treat patients that require replacement of antibodies to help provide protection against some infections. For treatment of some autoimmune disorders (diseases where the immune system is overactive). Panzyga® can only be obtained on a doctor’s ...
Manufactured by:Octapharma AG based inLachen, SWITZERLAND
octagam® 5% (50 mg/ml), Human Normal Immunoglobulin. octagam® 10% (100 mg/ml), Human Normal Immunoglobulin. Liquid, ready-to-use intravenous immunoglobulin ...
Manufactured by:MV BioTherapeutics SA based inBellinzona, SWITZERLAND
MV010/MV004, in cancer immunotherapy • Significant increase of tumor specific cytotoxic T cells infiltrating the tumor microenvironment by combining MV010/MV004 to anti-PD-L1 administration in murine models. • Significantly improved tumor eradication and resistance to subsequent grafting and improved survival in murine models. ...
Manufactured by:leadXpro AG based inVilligen, SWITZERLAND
Using X-ray structure-based molecular design, leadXpro has discovered, optimised and patented two new series of selective antagonists of the A2B adenosine receptor. ...
Manufactured by:BioLingus AG based inHergiswil, SWITZERLAND
The Cytokine Stabilisation and Slow Release (CSSR) technology is the "mother" of the BioLingus ...
by:Redbiotec AG based inSchlieren, SWITZERLAND
Redbiotec specializes in developing high-quality vaccines to fight difficult diseases. After successfully spinning out the CMV vaccine program that was acquired by Pfizer, Redbiotec is currently developing HSV-2 therapeutic vaccine ...
Manufactured by:BioLingus AG based inHergiswil, SWITZERLAND
Due to the fact that BioLingus drug administration is sublingual, and the use of a specific carrier molecule in the BioLingus formulation, the BioLingus technology is particularly effective for sublingual immuno ...
by:Stemline Therapeutics, Inc. based inNew York, NEW YORK (USA)
SL-701 is an immunotherapy designed to direct the immune system to attack targets present on certain malignancies including brain cancer. SL-701 comprises 3 short synthetic peptides that correspond to epitopes of targets including IL-13Rα2, EphA2, and survivin; 2 of these synthetic peptides (IL-13Rα2 and survivin) are mutant and believed to enhance immune activity. A multicenter Phase ...
Manufactured by:Elthera AG based inSchlieren, SWITZERLAND
L1 cell adhesion molecule (L1CAM) is a cell surface protein which is aberrantly expressed in many different tumor types including pancreatic, ovarian, breast, lung, and colorectal cancer. L1CAM expression increases the malignancy of these tumors by promoting cellular proliferation, metastatic spread, tumor angiogenesis, and resistance to chemotherapy. Accordingly, L1CAM-positive tumors ...
by:CDR-Life based inSchlieren, SWITZERLAND
CDR-Life’s T cell engaging antibodies are potentially transformative in the field of cancer immunotherapies» Prof. Markus G. Manz, MD, Head of Medical Oncology and Hematology at University Hospital and University of Zurich, Switzerland. CDR-Life’s pipeline is based on it’s unique antibody fragment platform. It includes a series of highly cancer-targeted and drug-based ...
Manufactured by:CanVirex AG based inBasel, SWITZERLAND
Oncolytic measles viruses as a multiplexed immune-modulating platform for cancer therapy. Cancer remains a medical and social burden worldwide despite several technological advances in the past decades. Conventional cancer treatments such as surgery, chemo-, or radiotherapy are restricted to local therapy or by dose-limiting toxicities and may induce drug resistance during treatment. In recent ...